Thx Pharma SA (ALTHX)

Currency in EUR
3.170
-0.020(-0.63%)
Real-time Data·
Advertisement
ALTHX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.1603.210
52 wk Range
0.9205.100
Key Statistics
Prev. Close
3.19
Open
3.21
Day's Range
3.16-3.21
52 wk Range
0.92-5.1
Volume
5.44K
Average Volume (3m)
110.04K
1-Year Change
256.1798%
Book Value / Share
0.21
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ALTHX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
5.800
Upside
+82.97%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 5.800
(+82.97% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
28/04/2026
EPS / Forecast
-0.07 / --
Revenue / Forecast
6.96K / --
EPS Revisions
Last 90 days

Compare ALTHX to Peers and Sector

Metrics to compare
ALTHX
Peers
Sector
Relationship
P/E Ratio
−14.9x−3.1x−0.4x
PEG Ratio
2.810.020.00
Price/Book
15.4x1.9x2.6x
Price / LTM Sales
55.4x9.2x3.0x
Upside (Analyst Target)
81.8%33.1%56.2%
Fair Value Upside
Unlock8.1%8.9%Unlock

THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease. The company was formerly known as Theranexus Société Anonyme and change its name to THX Pharma Société Anonyme in September 2025. The company was founded in 2013 and is headquartered in Lyon, France.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
57.96K0.42%192.73K
Other Institutional Investors
1.85M13.44%6.17M
Public Companies & Retail Investors
11.88M86.14%39.51M
Total
13.8M100.00%45.87M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Beyond Batten Disease Foundation6.51%898,4372,987
Auriga Partners4.55%627,7622,087

People Also Watch

47.65
ALSEM
-1.45%
0.2330
ALSEN
-0.64%
4.380
ALMDT
0.00%
1.0720
ALGID
0.00%
4.625
MEMS
-1.80%

FAQ

What Is the Thx Pharma (Paris: ALTHX) Share Price Today?

The Thx Pharma stock price today is 3.170 EUR.

What Stock Exchange Does Thx Pharma (ALTHX) Trade On?

Thx Pharma is listed and trades on the Paris Stock Exchange.

What Is the Ticker (Stock Symbol) for Thx Pharma?

The stock symbol (also called a 'ticker') for Thx Pharma is "ALTHX."

What Is the Current Thx Pharma Market Capitalisation?

As of today, Thx Pharma (Paris: ALTHX) market cap is 43.600M EUR.

What Is Thx Pharma's (ALTHX) Earnings Per Share (TTM)?

The Thx Pharma EPS is currently -0.218 (Trailing Twelve Months).

Is ALTHX a Buy or Sell From a Technical Analyst Perspective?

Based on today's Thx Pharma moving averages and other technical indicators, the daily buy/sell signal for ALTHX stock is Strong Sell.

How Many Times Has Thx Pharma Stock Split?

Thx Pharma has split 0 times. (See the ALTHX stock split history page for full effective split date and price information.)

How Many Employees Does Thx Pharma Have?

Thx Pharma has 12 employees, based on their latest Companies House report.

What is the current trading status of Thx Pharma (Paris: ALTHX)?

As of 26/06/2026, Thx Pharma (ALTHX) is trading at a share price of 3.170 EUR, with a previous close of 3.190 EUR. The stock has fluctuated within a day range of 3.160 EUR to 3.210 EUR, while its 52-week range spans from 0.920 EUR to 5.100 EUR.

What Is Thx Pharma (ALTHX) Price Target According to Analysts?

The average 12-month price target for Thx Pharma is 5.800 EUR, with a high estimate of 5.8 EUR and a low estimate of 5.8 EUR. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +82.97% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.